For all its challenges, 2020 was a transformative year in many ways. As our country continues to navigate the current challenges, including and especially the widespread impact of the COVID-19 pandemic, we have been heartened to see an overwhelming response to the CACNA1A Foundation’s work.

Joyce Lucas, MA, OTR/L writes about teaching a student with a CACNA1A variant to write her name independently utilizing low tech assistive technology for support.

This past weekend we hosted a booth in the nonprofit section of the virtual exhibit hall at the American Epilepsy Society’s (AES) annual meeting. This conference is the largest meeting and exhibition in the world for those who share the common scientific and clinical interests of epilepsy and clinical neurophysiology. AES typically attracts more than 5,000 attendees dedicated to improving the quality of life for people living with epilepsy. Our booth’s visitors included clinical neurologists, researchers, pharmaceutical companies, other rare disease groups and various epilepsy-related corporations. We made some excellent introductions and formed new relationships that will further our mission of accelerating CACNA1A research.

Many CACNA1A parents would argue a resounding, yes, there is a CACNA1A and autism connection. A quick search for “autism” in the CACNA1A/Cav 2.1 & Co. Facebook group reveals plenty of autism spectrum disorder (ASD) diagnoses and even more parents reporting autistic-like traits.

For those in the US, there is some exciting news regarding a new medication being developed for our children with Gain of Function variants. The CACNA1A Foundation recently had a call with Xenon Pharmaceuticals, a clinical-stage biopharmaceutical company committed to developing innovative therapeutics that will improve the lives of patients with neurological disorders and central nervous system (CNS) conditions, with a focus on epilepsy.